Author(s):
Sk. Mastanamma, Sure. Harika, Gula. Pavithra bai, SD. Anees begum
Email(s):
masthanamma.sk@gmail.com
DOI:
10.52711/0974-360X.2025.00853
Address:
Sk. Mastanamma1, Sure. Harika2, Gula. Pavithra bai3, SD. Anees begum4
1Department of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
2Department of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
3Department of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
4Department of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 12,
Year - 2025
ABSTRACT:
Objective: The aim of this study is to create and verify a high throughput approach for the detection of bexagliflozin in rat plasma by LC-MS/MS detection, and to apply this approach to pharmacokinetic studies. Method: The Waters Alliance HPLC system was used to achieve the chromatographic separation of Bexagliflozin using D6 – Bexagliflozin as the internal standard. A Quaternary gradient pump of the e2695 series, equipped with a Q-TRAP 5500 injector with 100ng/ml, was used to inject and elute the mobile phase, which contained 0.1% Formic acid and Acetonitrile in a 50:50 v/v ratio and was pumped at a flow rate of 1 ml/min. At room temperature, absorbance at 271 nm was used as a photodiode array detector for detection. Results: Retention time of 4.308 minutes were used to elute the peak of bexagliflozin. Over the Bexagliflozin concentration range of 10-200 ng/ml, the standard curves were linear. The relative standard deviation of the peak areas for all measurements was determined to be less than 2.0, meeting the acceptance criteria. The mean correlation coefficient was found to be 0.999. In conclusion, the method was used for pharmacokinetic study and validation; it was shown to be stable under the analytical conditions used and to fall within acceptable bounds for linearity, accuracy, and precision.
Cite this article:
Sk. Mastanamma, Sure. Harika, Gula. Pavithra bai, SD. Anees begum. Bioanalytical Method Development and Validation of Bexagliflozin in Rat Plasma by LC-MS/MS Detection and its Application to A Pharmacokinetic Studies. Research Journal Pharmacy and Technology. 2025;18(12):5906-0. doi: 10.52711/0974-360X.2025.00853
Cite(Electronic):
Sk. Mastanamma, Sure. Harika, Gula. Pavithra bai, SD. Anees begum. Bioanalytical Method Development and Validation of Bexagliflozin in Rat Plasma by LC-MS/MS Detection and its Application to A Pharmacokinetic Studies. Research Journal Pharmacy and Technology. 2025;18(12):5906-0. doi: 10.52711/0974-360X.2025.00853 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-12-43
REFERENCES:
1. Cappiello A, Famiglini G, Palma P, Pierini E, Termopoli V and Trufelli H. Overcoming Matrix effect in Liquid-Chromatography Mass spectrometry; Analytical Chemistry. 2008; 80: 9343-9348.
2. Hartmann C, Smeyers-Verbeke J, Massart DL and McDowall RD. Validation of bioanalytical chromatographic methods; Journal of Pharmaceutical and Biomedical Analysis. 1998; 17(2): 193-218,.
3. Pranay Wal, Brijesh Kumar, Anil Bhandari, A. K. Rai, and Ankita Wal. Bioanalytical method development- determination of drugs in biological fluids. Journal of Pharmaceutical Science and Technology. 2010; 2(10): 333 -347.
4. Sharma Devanshu, Mittal Rahul, Gupta Annu, Singh Kishan and Nair Anroop. Quantitative bioanalysis by LC-MS/MS: A review. Journal of Pharmaceutical and Biomedical Sciences. 2010; 7(7): 1-7.
5. Xu RN, Fan L, Rieser MJ and El-Shourbagy TA. Recent advances in high- throughput quantitative bio analysis by LC-MS/MS. Journal of Pharmaceutical and Biomedical analysis. 2007; 44(2): 342-355.
6. A. Kanaka Durga Valli, D. Sai Deepika, K.Atchuta Kumar. Estimation Of Bexagliflozin By Using RP-HPLC Method. World Journal of Pharmaceutical Sciences. 2023; 11(1): 9-20.
7. Kilaru, Govinda and Pagadala, Ramakanth and Gutta, Madhusudan and Kondabattula, Chandra and Rajkumar, S. and Gundekari, and Varkolu, Mohan. Efficient and Facile Synthesis of Bexagliflozin: An SGLT‐2 Inhibitor. Chemistry Select. 2024; 9. 10.1002/slct.202404188.
8. Cowart K, Coon S, Carris NW. A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes. Annals of Pharmacotherapy. 2023; 58(5): 514-522. doi:10.1177/10600280231190443
9. Megan Giruzzi, Ashley Worthey; Bexagliflozin. Clin Diabetes 2024; 42(1): 169–171.
10. Azzam, O., Carnagarin, R., Lugo-Gavidia, L. M., Nolde, J., Matthews, V. B., and Schlaich, M. P. Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opinion on Pharmacotherapy. 2021; 22(16): 2095–2103. https://doi.org/10.1080/14656566.2021.1959915